cutting cycle peptides FAQ

Verify dosing accuracy and administration timing first. Subcutaneous injection technique and peptide concentration errors are the most common protocol failures. If dosing is correct, evaluate baseline beta-adrenergic receptor sensitivity: chronic stimulant use, high-dose caffeine intake, or prior beta-agonist exposure can downregulate receptor density, reducing AOD-9604's lipolytic response. Consider a 10–14 day washout period from all adrenergic compounds before resuming the protocol. Subcutaneous fat loss from AOD-9604 is measurable by DEXA or skinfold caliper but may not translate to scale weight if lean tissue is maintained or increased through concurrent resistance training.

Store reconstituted AOD-9604 at 2–8°C and use within 14 days to prevent peptide degradation. Unlike larger peptides with complex tertiary structures, AOD-9604's short sequence is relatively stable in solution, but extended exposure to ambient temperature accelerates amide bond hydrolysis. Lyophilised powder can be stored at -20°C for up to 24 months without measurable potency loss, but once reconstituted, refrigeration is mandatory. Any cloudiness, discoloration, or precipitate formation indicates denaturation. Discard the vial and prepare a fresh solution.

Administer AOD-9604 in the fasted state 30–45 minutes before the first meal to maximize lipolytic signaling when endogenous insulin is lowest. The peptide's beta-adrenergic pathway is most active when insulin secretion is suppressed. Postprandial insulin blunts catecholamine-driven lipolysis by inhibiting hormone-sensitive lipase phosphorylation. Research designs pairing AOD-9604 for cutting cycle peptides research with time-restricted feeding consistently show greater fat oxidation rates than ad-libitum feeding protocols, though the interaction has not been isolated in controlled human trials.

Growth hormone increases aldosterone, the hormone that signals kidneys to retain sodium and water. This is temporary and dose-dependent. It peaks within 48–72 hours of administration and resolves as receptors downregulate. Reducing sodium intake to 2000–2500mg daily and increasing potassium to 3500–4500mg through dietary sources (spinach, avocado, salmon) re-establishes electrolyte balance without requiring diuretics. Water retention from GH is subcutaneous, not intramuscular. It doesn't obscure muscle definition the way estrogenic water retention does.

Peptides preserve muscle during deficits up to 30% below maintenance, but they don't override thermodynamics. Excessive deficits still cause metabolic slowdown and muscle loss. The optimal range for physique athletes is 20–25% below TDEE, paired with protein intake at 1.2–1.4g per pound of lean body mass. GH secretagogues allow you to sustain this deficit for 12–16 weeks without the thyroid crash that normally occurs at week 6–8.

Pituitary desensitization to exogenous secretagogues occurs around week 8–12 with continuous use. The solution is pulsed cycling: 5 days on, 2 days off, or 3 weeks on, 1 week off. This allows somatotroph cells to restore receptor density and endogenous pulsatility. Alternatively, rotating between different secretagogues (CJC to MK-677 to ipamorelin) prevents single-receptor desensitization because each compound acts through slightly different pathways.

Yes, but the mechanism shifts. Below 10% body fat, your body prioritizes muscle preservation over further fat loss. Thyroid output drops, testosterone declines, and cortisol rises to protect remaining energy stores. GH secretagogues counteract all three: they maintain T3 conversion, support Leydig cell testosterone production, and reduce cortisol's catabolic signaling. Research from the International Journal of Obesity shows GH administration during extreme caloric restriction (below 1200 calories) prevents the metabolic adaptation that normally occurs at sub-10% body fat levels.